In clinical trials of GLP-1 receptor agonists, the restricted mean survival time measures the actual amount of time patients live longer due to treatment, which is easier to understand than hazard...
Mechanism
Synthesis from 1 study
Doctors and patients can see exactly how many extra days a treatment gives them without a heart problem, instead of just hearing that risk went down by a percentage. This direct measure of time gained is easier to understand and use in real decisions.
Most probable mechanism
When a treatment extends life without heart problems, the total extra days gained can be measured directly, making it easier to understand than a percentage change in risk.
Cardiovascular events are timed and recorded as discrete occurrences in patient follow-up data.
The area under the survival curve up to a fixed time point is calculated to determine the average time lived without a cardiovascular event.
The difference in average time lived without an event between treatment and control groups is computed as an absolute value in days or months.
This absolute time difference is communicated to clinicians and patients as a tangible benefit, such as additional days of life free from heart attack or stroke.
Evidence from Studies
Supporting (1)
Community contributions welcome
Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.